Iron & Disease - Section 3

Iron supplementation in low-income countries

Andrew M. Prentice
MRC Unit The Gambia at LSHTM, Fajara, Gambia

Take Home Messages
- Iron deficiency anaemia (IDA) is the most common nutritional disorder worldwide and affects an estimated 1.2 billion people.
- Iron supplementation should be a practicable intervention in low-income countries but has very low efficacy and may cause harm by promoting infections.
- In the past 3 years the most likely mechanism by which iron supplementation increases malaria infection has been identified and reasons for the low efficacy are becoming clearer.

Introduction
The latest systematic analysis for the Global Burden of Disease Study 2016 estimated that 1.224 billion people worldwide suffer from iron deficiency anaemia (IDA). The consequences of iron deficiency (ID) and its associated anaemia are profound, ranging from early-life impairments in brain development, immune suppression and adverse pregnancy outcomes to lost productivity. IDA causes more years lived with disability than all other nutritional deficiencies, haemoglobinopathies and haemolytic anaemias combined. It is the leading cause of disability in many low- and middle-income countries (LMIC) and in most of sub-Saharan Africa.

IDA is usually ascribed to poor quality diets containing low amounts of bioavailable iron and high levels of anti-nutrients such as phytates and phenols (primary dietary iron deficiency), and/or infections such as malaria and intestinal parasites (secondary deficiency). Increasing the dietary diversity of poor populations is recommended as the optimal option for overcoming primary deficiency but is impractical in most settings due to cost. As the world’s population continues to rise it will also become increasingly difficult to provide the high quality (animal-based) foods that contain highly available iron. Thus supplementation with chemical forms of iron has been recommended for many decades as a pragmatic alternative and the World Health Organisation (WHO) recommends universal supplementation in population groups with a high prevalence of ID and IDA. However, iron supplementation programmes in LMICs suffer from low efficacy and evidence of harm.

Current state-of-the-art
Debates around the safety and efficacy of iron supplementation in LMICs have raged for the past decade since the publication of the, now infamous, Pemba Trial that was stopped prematurely by its data and safety monitoring board due to evidence of significant harm in the groups receiving iron. Other randomized trials have also reported evidence of harm and the problem has been widely debated. The latest research outputs on this topic are summarized below.

Malaria
The surprising evidence from epidemiological studies in children and pregnant women that IDA actually protects against malaria has been confirmed in ex vivo studies of Plasmodium falciparum parasite invasion and growth rates in red blood cells (RBCs) from anaemic children and pregnant women. These studies have also described the most likely mechanism by which iron supplementation increases the risk of malaria; namely that P. falciparum grows much better in reticulocytes and large young RBCs than in mature cells, particularly the prematurely-aged cells of iron deficiency anaemia. This is true both for laboratory and wild strains of the parasite. Remarkably it has been calculated that IDA offers much greater population protection against malaria than sickle cell trait.

Gut dysbiosis
Recent work by Zimmermann’s group at ETH Zurich, has consolidated their earlier demonstration that even low levels of iron as a fortificant (or as a supplement) can suppress the growth of beneficial gut organisms (lactobacilli and bifidobacteria) and enhance the growth of potential pathogens, as well as increasing gut inflammation. This represents a major challenge to iron supplementation programs and may explain observations in several studies that iron administration increases diarrhea. It might also explain some of the low compliance to iron supplements ascribed to gastric discomfort. Importantly the same group have shown that the co-administration of prebiotic galacto-oligosaccharide (GOS) with iron mitigates the adverse effects of iron on the gut microbiome and also enhances the absorption of iron. If replicated in further studies this would appear to offer a promising way forward. An alternative, or complementary, approach would be to design iron compounds that retain their bioavailability for humans but are...
unavailable to the gut microbiota. One such compound, iron hydroxide adipate tartrate\(^\text{17}\) is currently undergoing trials in rural African children.

**Debates about the efficacy of iron supplementation**

Numerous recent randomised trials with various formulations of iron supplements or point-of-eating food fortification (usually within multiple micronutrient powders) have shown very poor efficacy against ID and IDA.\(^\text{18,19}\) It must be assumed that the effectiveness of real-world programs would be even worse. Meta-analyses of trials in young children indicate a rise in hemoglobin of only between 3 and 5 g/L.\(^\text{20}\) Figure 1 shows that this would achieve only a very small correction of the hemoglobin deficit shown by typical rural African children. The benefit looks a little more impressive when quoted as a reduction in the proportion of children below the anemia cut-off of 110 g/L and hence these numbers are often cited. However, Verhooft et al.\(^\text{19}\) have argued that the public health gain from such programs must be measured using the continuous variable of hemoglobin because the dichotomous metric of anaemia percent overemphasizes the benefit.

**New insights from hepcidin biology**

The discovery of hepcidin and the emergent understanding of its regulation and effector actions are providing critical new insights into the challenges surrounding iron supplementation in low-income countries.\(^\text{21}\) In brief, because hepcidin inhibits intestinal iron absorption and is itself upregulated by inflammation,\(^\text{22}\) it can cause a complex ‘secondary’ anaemia of inflammation that co-exists with primary dietary iron deficiency. This has numerous implications both for the assessment and classification of ID and IDA,\(^\text{23}\) and for their prevention and treatment (discussed below).

**Future perspectives**

Given the harmful effects of ID/IDA and its enormous worldwide prevalence there is an urgent need to find really effective new solutions and to solve the policy impasse. Our research team has recent evidence that even very low-grade inflammation leads to hepcidin-mediated blockade of iron absorption in young African children living in unclean environments. These fresh insights, driven by the discovery of hepcidin, have potentially important implications for breaking through the roadblock of poor efficacy.

Ultimately, they demonstrate that in the special case of iron, whose absorption is so exquisitely regulated, nutrition-specific interventions will not succeed in the absence of so-called nutrition sensitive interventions to clean up children’s living conditions and markedly reduce their levels of inflammation.

On the pathway to this end there are some clear intermediary research questions to be examined. What are the underlying causes of the inflammation? Surprisingly our data reveal no signal from the gut but very strong signals from fevers and respiratory illnesses. Is it possible to devise any safe anti-inflammatory interventions ahead of the ultimate goal of achieving western standard living conditions? Finally, might orally-active hepcidin antagonists one day emerge as new tools against ID and IDA in low income settings?

**References**

1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017;390:1211-1259.
2. WHO. Conclusions and recommendations of the WHO consultation on prevention and control of iron deficiency in infants and young children in malaria endemic areas. Food Nutr Bull 2007;28:S621-7.
3. WHO. Guideline: Use of multiple micronutrient powders for point-of-use fortification of foods consumed by infants and young children aged 6-23 months and children aged 2-12 years. Geneva: WHO; 2016.
4. Sazawal S, Black RE, Ramsan M, et al. Effects of routine prophylactic supplementation with iron and folic acid on admission to hospital and mortality in preschool children in a high malaria transmission setting: community based, randomised, placebo controlled trial. Lancet 2006;367:133–43.
5. Prentice AM. Iron metabolism, malaria, and other infections: what is all the fuss about? J Nutr 2008;138:2537-41.
6. Jaeggi T, Kortman GAM, Moretti D, et al. Iron fortification adversely affects the gut microbiome, increases pathogen abundance and induces intestinal inflammation in Kenyan infants. Gut 2015;64:731-42.
7. Zlotkin S, Newton S, Aimone AM, et al. Effect of iron fortification on malaria incidence on infants and young children in Ghana: A randomised trial. JAMA 2013;310:938-47.
8. Zlotkin S, Newton S, Aimone AM, et al. Effect of iron fortification on malaria incidence on infants and young children in Ghana: A randomised trial. JAMA 2013;310:938-47.
9. Soofi S, Cousins S, Iqlbal SP, et al. Effect of provision of daily zinc and iron with several micronutrients on growth and morbidity leading young children in Pakistan: a cluster-randomised trial. Lancet 2013;382:29-40.
10. Kwamboka M, Kurits JD, Sorensen BE, et al. Iron deficiency protects against severe Plasmodium falciparum malaria and death in young children. Clin Infect Dis 2012;54:1137-44.
*11. Goheen MM, Wegmüller R, Bah A, et al. Anaemia offers stronger protection than sickle cell trait against the erythrocytic stage of falciparum malaria and this protection is reversed by iron supplementation. EBioMedicine 2016;14:123-30.

This study demonstrated how powerful is the protective effect of IDA against Falciparum malaria.

12. Goheen MM, Bah A, Wegmüller R, et al. Host iron status and erythropoietic response to iron supplementation determines susceptibility to the RBC stage of falciparum malaria during pregnancy. Sci Rep 2017;7:17674.

*13. Clark MA, Goheen MM, Fulford A, et al. Host iron status and iron supplementation mediate susceptibility to erythrocytic stage Plasmodium falciparum. Nat Commun 2014;5:4446.

This paper (later extensively confirmed in ref 12) proposes the mechanism by which IDA protects against malaria and iron supplementation increases the risk of serious infection.

*14. Zimmermann MB, Chassard C, Rohner F, et al. The effects of iron fortification on the gut microbiota in African children: a randomised controlled trial in Cote d’Ivoire. Am J Clin Nutr 2010;92:1406–15.

This paper (later confirmed by ref 5 and other papers by this research group) first showed that iron supplementation causes gut dysbiosis.

*15. Paganini D, Uyoga MA, Kortman GAM, al. Prebiotic galactooligosaccharides mitigate the adverse effects of iron fortification on the gut microbiome: a randomised controlled study in Kenyan infants. Gut 2017;66:1956-67.

Together with ref 16 these papers show that administration of GOS can ameliorate the dysbiotic effects of supplementary iron and improve iron absorption.

16. Paganini D, Uyoga MA, Cercamondi CI, et al. Consumption of galacto-oligosaccharides increases iron absorption from a micronutrient powder containing ferrous fumarate and sodium iron EDTA: a stable-isotope study in Kenyan infants. Am J Clin Nutr 2017;106:1020-31.

17. Pereira DI, Bruggaber SF, Faria N, et al. Nanoparticulate iron(III) oxo-hydroxide delivers safe iron that is well absorbed and utilised in humans. Nanomedicine 2014;10:1877-86.

18. Teshome EM, Andang’o PEA, Osoti V, et al. Daily home fortification with iron as ferrous fumarate versus NaFeEDTA: a randomised, placebo-controlled, non-inferiority trial in Kenyan children. BMC Med 2017;15:89.

19. Verhoef H, Teshome E, Prentice AM. Micronutrient powders to combat anaemia in young children: do they work? BMC Med 2018;16:7.

20. Pasricha SR, Hayes E, Kalumba K, Biggs BA. Effect of daily iron supplementation on health in children aged 4-23 months: a systematic review and meta-analysis of randomised controlled trials. Lancet Glob Health 2013;1:e77-86.

21. Prentice AM. Clinical implications of new insights into hepcidin-mediated regulation of iron absorption and metabolism. Ann Nutr Metab 2017;71(Suppl 3):40-8.

22. Drakesmith H, Prentice AM. Hepcidin and the iron-infection axis. Science 2012;338:768-72.